"Sales" require regulatory approval. The good thing about this news is that this site already has experience utilising the device from a prior trial, so we can expect further recruitment of patients in the TRIPP-FFX trial, which from my understanding, would be the next step towards regulatory approval.
Not a bad way to end the year - enjoy a Happy New Year everyone, let's see how 2025 goes for patients and shareholders alike!
Ann: First Patient in Australia Randomised in TRIPP-FFX Trial, page-3
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
95.0¢ |
Change
0.010(1.06%) |
Mkt cap ! $13.51M | |||
| Open | High | Low | Value | Volume |
| 95.0¢ | $1.02 | 94.0¢ | $110.7K | 114.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15628 | 95.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.00 | 1909 | 2 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |